PURPOSE: Treatment of acute lung injury (ALI) observed in Gram-negative sepsis represents an unmet medical need due to a high mortality rate and lack of effective treatment. Accordingly, we developed and characterized a novel nanomedicine against ALI. We showed that when human glucagon-like peptide 1(7-36) (GLP-1) self-associated with PEGylated phospholipid micelles (SSM), the resulting GLP1-SSM (hydrodynamic size, ~15 nm) exerted effective anti-inflammatory protection against lipopolysaccharide (LPS)-induced ALI in mice. METHODS: GLP1-SSM was prepared by incubating GLP-1 with SSM dispersion in saline and characterized using fluorescence spectroscopy and circular dichroism. Bioactivity was tested by in vitro cAMP induction, while in vivo anti-inflammatory effects were determined by lung neutrophil cell count, myeloperoxidase activity and pro-inflammatory cytokine levels in LPS-induced ALI mice. RESULTS: Amphipathic GLP-1 interacted spontaneously with SSM as indicated by increased α-helicity and fluorescence emission. This association elicited increased bioactivity as determined by in vitro cAMP production. Correspondingly, subcutaneous GLP1-SSM (5-30 nmol/mouse) manifested dose-dependent decrease in lung neutrophil influx, myeloperoxidase activity and interleukin-6 in ALI mice. By contrast, GLP-1 in saline showed no significant anti-inflammatory effects against LPS-induced lung hyper-inflammatory responses. CONCLUSIONS: GLP1-SSM is a promising novel anti-inflammatory nanomedicine against ALI and should be further developed for its transition to clinics.
PURPOSE: Treatment of acute lung injury (ALI) observed in Gram-negative sepsis represents an unmet medical need due to a high mortality rate and lack of effective treatment. Accordingly, we developed and characterized a novel nanomedicine against ALI. We showed that when humanglucagon-like peptide 1(7-36) (GLP-1) self-associated with PEGylated phospholipid micelles (SSM), the resulting GLP1-SSM (hydrodynamic size, ~15 nm) exerted effective anti-inflammatory protection against lipopolysaccharide (LPS)-induced ALI in mice. METHODS:GLP1-SSM was prepared by incubating GLP-1 with SSM dispersion in saline and characterized using fluorescence spectroscopy and circular dichroism. Bioactivity was tested by in vitro cAMP induction, while in vivo anti-inflammatory effects were determined by lung neutrophil cell count, myeloperoxidase activity and pro-inflammatory cytokine levels in LPS-induced ALI mice. RESULTS: Amphipathic GLP-1 interacted spontaneously with SSM as indicated by increased α-helicity and fluorescence emission. This association elicited increased bioactivity as determined by in vitro cAMP production. Correspondingly, subcutaneous GLP1-SSM (5-30 nmol/mouse) manifested dose-dependent decrease in lung neutrophil influx, myeloperoxidase activity and interleukin-6 in ALI mice. By contrast, GLP-1 in saline showed no significant anti-inflammatory effects against LPS-induced lung hyper-inflammatory responses. CONCLUSIONS:GLP1-SSM is a promising novel anti-inflammatory nanomedicine against ALI and should be further developed for its transition to clinics.
Authors: R T Sadikot; E D Jansen; T R Blackwell; O Zoia; F Yull; J W Christman; T S Blackwell Journal: Am J Respir Crit Care Med Date: 2001-09-01 Impact factor: 21.405
Authors: Rebecca M Baron; Irvith M Carvajal; Laura E Fredenburgh; Xiaoli Liu; Yolanda Porrata; Michael L Cullivan; Kathleen J Haley; Larry A Sonna; George T De Sanctis; Edward P Ingenito; Mark A Perrella Journal: FASEB J Date: 2004-06-18 Impact factor: 5.191
Authors: Fiona E Yull; Wei Han; E Duco Jansen; M Brett Everhart; Ruxana T Sadikot; John W Christman; Timothy S Blackwell Journal: J Histochem Cytochem Date: 2003-06 Impact factor: 2.479
Authors: Bomy Lee Chung; Michael J Toth; Nazila Kamaly; Yoshitaka J Sei; Jacob Becraft; Willem J M Mulder; Zahi A Fayad; Omid C Farokhzad; YongTae Kim; Robert Langer Journal: Nano Today Date: 2015-12-01 Impact factor: 20.722